COMMUNIQUÉS West-GlobeNewswire

Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
21/07/2026
The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks gestation SALT LAKE CITY, July 21, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular [...]
SK pharmteco et Généthon mettent en avant l’excellence de la fabrication française à l’origine du programme pivot de thérapie génique contre la DMD
21/07/2026
Le soutien continu apporté au GNT-0004 souligne la capacité, la préparation et la dynamique soutenue des activités de SK pharmteco dans le domaine des vecteurs viraux en France, au sein de son réseau mondial RANCHO [...]
The National Upper Cervical Chiropractic Association Celebrates 60 Years of Restoring Balance from the Top Down, Creating Optimal Function and Health
21/07/2026
SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) -- A legacy of longevity. This year, the National Upper Cervical Chiropractic Association (NUCCA) celebrates six decades of advancing education and professional standards [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
21/07/2026
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 21 juillet 2026 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ) la Specialty Pharma qui [...]
Exagen to Announce Second Quarter Financial Results on August 4, 2026
21/07/2026
CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026, before the market [...]
OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
21/07/2026
LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
21/07/2026
Preliminary data reinforces IMNN-001 immunotherapy’s potential for success in the rapidly recruiting Phase 3 OVATION 3 clinical trial Lower rate of minimal residual disease (MRD) Higher ctDNA clearance with IMNN-001 vs [...]
Revagenix Expands Executive Team, Names Peter Smith, Ph.D., Chief Scientific Officer as Lead Program Enters the Clinic
21/07/2026
Rev-56 scientific leader promoted to CSO to advance Revagenix’s scientific strategy in non-cystic fibrosis bronchiectasis and other serious chronic diseases SAN FRANCISCO, July 21, 2026 (GLOBE NEWSWIRE) -- Revagenix, [...]
Nelipak Releases 2025 Sustainability Report
21/07/2026
Highlights achievements aligned to sustainability vision to “help healthcare be sustainable.” CRANSTON, R.I., July 21, 2026 (GLOBE NEWSWIRE) -- Nelipak® Corporation (“Nelipak ® ”), a leading global provider of [...]
Communiqué de presse : Sanofi fait évoluer son Comité exécutif pour préparer son prochain chapitre stratégique
21/07/2026
Sanofi fait évoluer son Comité exécutif pour préparer son prochain chapitre stratégique Paris, le 21 juillet 2026. Sanofi annonce aujourd’hui une évolution de la composition de son Comité exécutif. Cette évolution donne [...]
Three Peat: USOSM Recognized as One of the Region’s Fastest Growing Companies by Dallas Business Journal
21/07/2026
IRVING, Texas, July 21, 2026 (GLOBE NEWSWIRE) -- For the third year in a row, Irving’s U.S. Oral Surgery Management ( USOSM ) has secured a spot on the Dallas Business Journal’s list of the region’s fastest growing [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
21/07/2026
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 21 juillet 2026 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ) la Specialty Pharma qui [...]
Stereotaxis to Report Second Quarter 2026 Financial Results on August 11, 2026
21/07/2026
ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2026
21/07/2026
Aggregated presentation by day and by market Weekly report on share repurchases from 13th July to 17th July 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument [...]
SK pharmteco and Genethon Showcase French Manufacturing Strength Behind Pivotal DMD Gene Therapy Program
21/07/2026
Ongoing support for GNT-0004 highlights the capability, readiness, and continued momentum of SK pharmteco’s viral vector operations in France as part of its global network RANCHO CORDOVA, Calif., July 21, 2026 (GLOBE [...]
Choosing a Shaker Bottle for Thick Pre-Workout Powders: What Actually Prevents Clumping
21/07/2026
PROMIXX set out to fix what defined the manual shaker category, replacing the wire mixing ball with the Snap-Fit Agitator: a lid-locked mixing grid Cardiff, July 21, 2026 (GLOBE NEWSWIRE) -- The Snap-Fit Agitator is an [...]
Philips receives FDA 510(k) clearance for next-generation reusable SpO₂ clip sensor
21/07/2026
July 21, 2026 New sensor advances pulse oximetry reliability for diverse patient populations through innovation and rigorous validation. Cambridge, MASS – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health [...]
CROSSJECT : Information relative au nombre total de droits de vote et d'actions composant le capital social
21/07/2026
Communiqué de Presse Information relative au nombre total de droits de vote et d’actions composant le capital social Dijon, le 21 juillet 2026 CROSSJECT (ISIN : FR0011716265 ; Mnémo : ALCJ) la Specialty Pharma qui [...]
NeuroSigma Announces U.S. Commercial Launch of Second-Generation Monarch® eTNS System for Pediatric ADHD
21/07/2026
U.S. Commercial launch of Gen 2 Monarch System commencing today, July 21, 2026 Gen 2 Monarch device provides an enhanced patient experience while delivering clinically proven therapeutic stimulation of the trigeminal [...]

Pages